

Workshop on Vaccination and Alternatives to Antimicrobials for English Speaking Africa

28 - 30 October 2025, Entebbe, Uganda






Outline

- **GALVmed** at a glance
- Ongoing **Activities**
- **Better Regulation Project** & Role of WOA



World Organisation
for Animal Health



PROTECTING LIVESTOCK IMPROVING HUMAN LIVES



Protecting Livestock - Improving Human Lives

galvmed.org

Workshop on Vaccination and Alternatives to
Antimicrobials for English Speaking Africa

28 - 30 October 2025, Entebbe, Uganda



Sources: World Bank, FAO & OIE



Fastest growing, highest-value agricultural subsector globally.



70% of the rural poor depend on livestock for income (FAO).



Greater demand for animal-derived protein.



Growing business interest in sub-Saharan Africa and South Asia.



Help to **address stunting** in children.



Prospects for **rural employment, women and youth**.



Over 20% of animal production losses are linked to infectious animal diseases.



Increased need for **greater efficiency** in livestock production.



Vaccines prevent and manage **antimicrobial resistance**.



Better **use and access** of veterinary medicine can improve **One Health**.



Our vision is...

transformational improvement in the wellbeing and **economic** progression of **smallholder** livestock farmers.

Our mission is...

to contribute to the transformation of smallholder farmers' lives by:

Understanding the constraints to animal health and how to overcome them.

Engaging the animal health industry.

Ensuring **awareness, availability & adoption** of effective animal health interventions.

? WHAT

- An Animal Health product and business development.
- International non for-profit organization.




? WHY

- **Transformational improvement** in the wellbeing and economic progression of small-scale livestock producers (SSPs)
- **Improve access to veterinary products** SSPs in sub-Saharan Africa and the Indian subcontinent.



? HOW


- **Understanding barriers to entry** to animal health and how to overcome them.
- **Engaging** animal health industry stakeholders.
- **Awareness, availability & adoption** of effective animal health interventions.





1. Research & Development: Facilitating partnerships with universities, research institutes, and the private sector to develop high impact health interventions.

2. Commercial Development: Working with private sector partners who are willing to develop sustainable and scalable business models that focus on serving SSP segments.



Progress at scale must happen via **markets.**

3. Favorable Policy **Trained Frontline Vets** **Robust Markets**

4. Data & Monitoring

3. Enabling Environment: Working with advocacy groups, regulators, the animal health industry and government bodies to ease barriers in the regulatory and market environment.

4. Monitoring & Evaluation: Delivering pragmatic data and information from the SSP field which quantifies impact and informs strategy and operational plans.

DISEASE PRIORITIES

- Infectious diseases that severely constrain small-scale livestock production (poultry, sheep, goat, cattle and swine).



COUNTRIES

- We prioritize a set of 4-5 Tier 1 countries. (Kenya, Tanzania and Nigeria).
- Support commercial partners taking a broader and more regional approach.





BY 2030 GALVMED WILL HAVE ACHIEVED:

1. Through R&D activities

A significantly enhanced portfolio of SSP products and technologies.



2. Through CD activities

Transformed supply and uptake of key animal health products for the SSP segment.



3. Through R&D, CD, EE activities

Tangible investment and engagement in the SSP segment by the animal health industry.



Overarching Objective: significantly improved livestock health and productivity → lives & livelihoods of millions of SSPs materially improved in terms of economic benefit.

OVERARCHING OBJECTIVE: HEADLINE OBJECTIVES BY 2030

1

- 24 New products.
- 3 New technologies.
- 1 Product dev. Platform.
- 3 Manufacturers facilitated.

2

- 200 product registrations.
- 15 manufacturers engaged in SSP distribution platforms.

3

- 60% availability of 'necessary' product inventory.
- 80%, 50% adoption of available 'essential'/'advisory' products.
- 10 Million SSP customers served with key products and services.
- \$73 average economic benefit per SSP customer.

\$730 MILLION SSP WEALTH CREATED



Improving Access To Quality Veterinary Products Via **Better Regulation**

- Led by GALVmed with UK-VMD, WOAHA and EAC as partners.
- Project start date, 1st June 2024, 36 months funding.

Core themes and milestones


- 1) SSA Governance Structure: decision made on need and form of governance structure (31st May 2025); agreement from potential host (31st May 2026); and funding strategy in place (31st May 2027)**
- 2) SA tool: decision by WOAHA Members to support global adoption of the SA tool (31st May 2027)**
- 3) EAC MRP: systems in place that can monitor EAC MRP performance and clear pathway to sustainability (31st May 2025); additional countries adopted into MRP (31st May 2027)

Vision by 2030

Looking beyond this project, the vision is that by 2030:

- A sustainable Governance structure for SSA will be in place with clear leadership from countries in the region.
- Capacity building funding will have been secured to address gaps identified by the self-assessment tool in at least two countries.
- Two additional EAC countries will be participating as Concerned Countries in the MRP.

Pathway towards 2030





World Organisation
for Animal Health



If you want to know more
about us, please visit:
www.galvmed.org



GALVmed



@GALVmed



GALVmed



**Workshop on Vaccination and Alternatives to
Antimicrobials for English Speaking Africa**

28 - 30 October 2025, Entebbe, Uganda

